Teva's DEGEVMA Biosimilar to Challenge Sandoz's Wyost in Oncology Market
Teva Pharmaceutical Industries has secured US FDA approval for its biosimilar DEGEVMA (denosumab-adet), which is a copy of Amgen's Xgeva. The drug will be used to prevent bone complications in adults with cancer that has spread to the bones, as well as treat giant cell tumor of bone. Sandoz had already received approval for its biosimilar Wyost (denosumab-bbdz) in March 2024, giving it a head start in formulary negotiations.
Xgeva generated $2.08 billion in sales for full-year 2025, but Amgen's revenue is declining at a rate of six percent year-over-year. Teva's DEGEVMA will compete with Sandoz's Wyost in the oncology market, which keeps it separate from the osteoporosis market served by Prolia biosimilars.
The question now is whether DEGEVMA can close the formulary gap against Wyost through pricing. Without interchangeable designation, Teva likely needs deeper discounts or existing institutional relationships to gain meaningful volume.